Innoviva, Inc. subsidiary Entasis Therapeutics Holdings Inc. appears to be headed for an easy US Food and Drug Administration advisory panel for its combination antibacterial sulbactam-durlobactam (SUL-DUR) on 17 April, but it won’t be for the more lucrative pathogen-specific indication the company wanted.
The Antimicrobial Drugs Advisory Committee will vote on whether the overall benefit-risk assessment is favorable for use of SUL-DUR in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?